Vigonvita Life Sciences Co., Ltd.
2630.HK
Hong Kong Stock Exchange58.65
HKD
-2.15
- -
ISIN
CNE1000076N3
Return %
Stock
S&P500
1Y
-28.48
23.08
3Y
-28.48
67.59
5Y
-28.48
74.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Guanghui Tian
- Full Time Employees
- 315
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Building A Suzhou JS People's Republic of China 215021
- IPO Date
- Nov 6, 2025
- Website
- vigonvita.cn
- Similar Companies
- Business
- Vigonvita Life Sciences Co., Ltd. is a research-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics in neuropsychiatry, reproductive health, and viral infections. The company advances an integrated pipeline across lead discovery, druggability optimization, preclinical evaluation, and clinical development, with a portfolio that includes multiple small-molecule programs and antiviral candidates targeting urgent unmet medical needs. Its lead assets and late-stage programs concentrate on first-in-class and best-in-class mechanisms, including compounds in Phase II and Phase III clinical development and several preclinical candidates advancing toward human testing. Headquartered in Shanghai, with primary operations in Suzhou and Shanghai, Vigonvita operates an end-to-end platform encompassing innovative drug discovery, translational research, manufacturing readiness, and clinical application. The company emphasizes end-to-end capabilities through its in-house teams and partners, enabling rapid progression from lead identification to clinical trial execution and eventual commercialization. Vigonvita’s geographic footprint and strategic collaborations support its aim to address global markets, with a focus on neuropsychiatric disorders, fertility and reproductive health, and viral infections. Founded in 2013, Vigonvita maintains its headquarters in Shanghai and maintains a significant presence in Suzhou, positioning itself as a regional hub for integrated biopharmaceutical development. The company pursues strategic partnerships, potential licensing arrangements, and collaborations to accelerate development timelines, expand its global reach, and strengthen its pipeline through shared expertise, resources, and capital investment. Vigonvita’s operating model relies on a combination of internally developed drug programs and externally partnered initiatives to optimize value creation across its therapeutic focus areas.